Wision A.I. Expands U.S. Offerings to Combat Colorectal Cancer With Multiple Screening Tools
SHANGHAI, March 22, 2022 (GLOBE NEWSWIRE) -- Wision A.I. Ltd, a startup in the field of artificial intelligence assisted diagnostics for optical medical imaging, today announced the expansion of its product portfolio with recent U.S. Food & Drug Administration (FDA) 510(k) Clearance for EndoScreener, its AI-assisted polyp detection software during colonoscopy, and an FDA presubmission in queue for an upcoming histopathology AI software that assists in the localization of high-grade dysplasia (HGD) in whole slide imaging (WSI).
- Wision A.I.s new histopathological AI product is used to localize HGD, the cancerous characteristics, in histologic whole slide imaging (WSI) for colorectal specimens.
- To learn more about Wision AI, please email [email protected]
i Colorectal cancer statistics: How common is colorectal cancer? - Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity [published correction appears in Cancer.
- Cancer.